3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
35
Recruiting
26
Terminated
16
Active not recruiting
14
Withdrawn
8
Unknown
5
Suspended
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Interventions
Specimen Handling
29
Magnetic Resonance Spectroscopy
18
Biopsy
16
Cyclophosphamide
15
Nivolumab
10
Paclitaxel
9
Vincristine
8
Cisplatin
8
venetoclax
7
Prednisone
7
Gemcitabine
7
Doxorubicin
7
Bevacizumab
7
Azacitidine
7
pembrolizumab
6
Radiotherapy
6
Fluorouracil
6
Etoposide
6
Drug Therapy
6
Docetaxel
6
Rituximab
5
Radiosurgery
5
Oxaliplatin
5
Irinotecan
5
Injections
5
Everolimus
5
Capecitabine
5
fludarabine phosphate
4
Taxes
4
Surgical Procedures, Operative
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Suspended
×
Interventional
×
talazoparib
×
Clear all
NCT05425862
2023-12-11
REPAIR
Peter MacCallum Cancer Centre, Australia
Phase 1
Suspended
48 enrolled